Jens Bauer

Postdoc – Head of Research

Universitätsklinikum Tübingen

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jens Bauer is a Postdoctoral Researcher and Head of Research at Universitätsklinikum Tübingen, Germany. His research focuses on immunopeptidomics and peptide-based immunotherapy, evidenced by his recent publications in areas including immunopeptidome databases, personalized peptide vaccines, and immune responses in various cancers and COVID-19. Dr. Bauer is dedicated to advancing the understanding of immune surveillance and therapeutic strategies through innovative clinical trial designs.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (4)

Michael Daskalakis

Assistant Professor, Head of Cellular Therapy Division, Director of autologous Stem Cell Program Inselspital

Inselspital Universitätsspital Bern

SWITZERLAND

View details

Yacine Maringer

University of Tuebingen

GERMANY

View details

Susanne Rittig

Charité - Universitätsmedizin Berlin

GERMANY

View details

Annika Nelde

University Hospital Tübingen

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jens Bauer

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development

Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients

Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade

FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts

Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells

TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification

Immunoprecipitation methods impact the peptide repertoire in immunopeptidomics

Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity

Collaborators (4)

Michael Daskalakis

Yacine Maringer

Susanne Rittig

Annika Nelde

Make your next move.